SPI-POZ-101: Poziotinib in HER2 Positive Breast Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

SPI-POZ-101: Poziotinib in HER2 Positive Breast Cancer

Sponsor: Spectrum Pharmaceuticals, Inc

SPI-POZ-101 is a trial of the oral tyrosine kinase inhibitor poziotinib in combination with intravenous administration of HER2 targeted anti-body TDM-1 for the treatment of locally advanced or metastatic HER2 positive breast cancer that has previously been treated with an anti-HER2 directed therapy.